<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Extragonadal germ cell tumors involving the mediastinum and retroperitoneum
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Extragonadal germ cell tumors involving the mediastinum and retroperitoneum
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Extragonadal germ cell tumors involving the mediastinum and retroperitoneum
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Darren Feldman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy D Gilligan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germ cell tumors (GCTs) are classified as extragonadal if there is no evidence of a primary tumor in the testes or ovaries [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Extragonadal GCTs typically arise in midline locations, and specific sites vary with age. In adults, the most common sites, in order of frequency, are the anterior mediastinum, the retroperitoneum, and the pineal and suprasellar regions. In infants and young children, sacrococcygeal and intracranial GCTs are most common.
        </p>
        <p>
         Mediastinal and retroperitoneal GCTs are reviewed here. The approach to the adult patient with a mediastinal mass, the pathology of mediastinal tumors, intracranial GCTs, and sacrococcygeal teratoma are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6967.html" rel="external">
          "Approach to the adult patient with a mediastinal mass"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5199.html" rel="external">
          "Intracranial germ cell tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5200.html" rel="external">
          "Sacrococcygeal teratoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H198908833">
         <span class="h1">
          PATHOLOGIC DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extragonadal GCTs are classified as seminomas (termed dysgerminomas in females), nonseminomatous GCTs (termed nondysgerminomas in females), mature teratomas, and immature teratomas based upon histology [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seminomas
         </strong>
         – Seminomas and dysgerminomas must be distinguished from nonseminomatous and nondysgerminomatous GCTs because of the differences in prognosis and treatment. In children, these tumors are often referred to as germinomas and nongerminomas. For a tumor to be considered a seminoma, dysgerminoma, or germinoma, it must consist entirely of that single histology and cannot contain other GCT elements.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonseminomatous tumors
         </strong>
         – The nonseminomatous tumors, including nondysgerminomas and nongerminomas, include yolk sac tumors, choriocarcinomas, embryonal carcinomas, teratomas, and mixed tumors that contain more than one cell line. Mixed tumors that contain an element of seminoma (or dysgerminoma/germinoma) are classified as nonseminomatous GCTs (or nondysgerminomas/nongerminomas).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Teratomas
         </strong>
         – Mature teratomas of the mediastinum generally behave in an indolent manner, unlike testicular GCTs, where there is no clear prognostic distinction between mature and immature teratoma. In adults, immature teratomas of the mediastinum can be aggressive tumors, similar to other nonseminomas, and have a poor prognosis, whereas in prepubertal children, immature elements in a teratoma are not associated with malignant behavior [
         <a href="#rid2">
          2,3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of extragonadal GCTs is not clearly defined. Two competing hypotheses have been proposed, but there are insufficient data to determine which, if either, is correct.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first hypothesis is that extragonadal GCTs are derived from primordial germ cells that fail to complete the normal migration along the urogenital ridge to the gonadal ridges during embryonal development. This may be due to an abnormality in the primordial germ cell itself or in its microenvironment [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The second hypothesis is that germ cells transformed in the testes undergo reverse migration [
         <a href="#rid5">
          5
         </a>
         ] or represent metastatic tumors that originated from primary testicular tumors that then burned out [
         <a href="#rid3">
          3
         </a>
         ]. This hypothesis is supported by genetic data suggesting that extragonadal GCTs and testicular GCTs share a common cell of origin [
         <a href="#rid6">
          6,7
         </a>
         ]. The evidence for this hypothesis is strongest for retroperitoneal GCTs [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, this hypothesis does not explain the biological differences seen in mediastinal nonseminomatous GCTs compared with nonseminomatous GCTs occurring in the testes or retroperitoneum. Such differences include the poorer prognosis and the greater incidence of yolk sac tumor elements and leukemia in patients with mediastinal primaries and might result from differences either in the cell of origin or in the tumor's microenvironment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A third hypothesis is that extragonadal GCTs arise from the thymus [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The following observations may be relevant to the pathogenesis of extragonadal GCTs:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testicular carcinoma in situ, the precursor of testicular GCTs, is found in up to 50 percent of the testes of males with retroperitoneal GCTs [
         <a href="#rid9">
          9
         </a>
         ]. However, testicular biopsy is not generally indicated in the absence of evidence of a tumor on ultrasonography [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3003.html" rel="external">
          "Testicular germ cell neoplasia in situ"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of developing a metachronous testicular GCT is significantly increased in males with extragonadal GCTs, particularly among those with retroperitoneal location and nonseminomatous histology (incidence ratios 100 and 75, respectively) [
         <a href="#rid11">
          11
         </a>
         ]. The cumulative risk of developing a metachronous testicular cancer is approximately 10 percent at 10 years after the diagnosis of an extragonadal GCT. (See
         <a class="medical medical_review" href="/z/d/html/3003.html" rel="external">
          "Testicular germ cell neoplasia in situ", section on 'Extragonadal germ cell tumor'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H52591605">
         <span class="h1">
          RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H1012877967">
         <span class="h2">
          Klinefelter syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males with Klinefelter syndrome (KS; 47,XXY) have an increased risk for GCTs, particularly those arising in the mediastinum [
         <a href="#rid12">
          12-14
         </a>
         ]. Although it is not standard practice since the absolute risk is low, clinicians may opt to screen males with KS for mediastinal GCTs [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13921.html" rel="external">
          "Clinical features, diagnosis, and management of Klinefelter syndrome", section on 'Comorbidities'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16974.html" rel="external">
          "Sex chromosome abnormalities", section on '47,XXY Klinefelter syndrome'
         </a>
         .)
        </p>
        <p>
         In one report from the Children's Oncology Group (COG), approximately 3 percent of pediatric males with a GCT had KS and 69 percent of those GCTs arose in the mediastinum. Among the patients with mediastinal GCTs, approximately one-third had KS. The risk of developing a GCT between ages 0 and 19 years among males with KS was estimated to be 1:4000 per year, which is 19 times higher than the risk among males without KS.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extragonadal GCTs are typically diagnosed with a needle or open biopsy prior to treatment. In rare cases, emergency treatment may be initiated because of severe symptoms before a tissue diagnosis is obtained, based upon tumor markers and the distribution of disease. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors", section on 'Germ cell tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H157771">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two key issues in establishing the diagnosis are the exclusion of metastasis from a primary testicular GCT and distinguishing an extragonadal nonseminomatous GCT from another type of poorly differentiated cancer:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastases from a primary testicular GCT
         </strong>
         – It may be difficult to distinguish true extragonadal GCTs from metastatic tumors in which the primary gonadal lesion has regressed [
         <a href="#rid16">
          16,17
         </a>
         ]. Testicular palpation is not sufficient to exclude a primary testicular GCT; ultrasonography should be performed in all patients [
         <a href="#rid18">
          18
         </a>
         ]. However, a tumor involving the anterior mediastinum is unlikely to be a metastasis from a testicular primary. Primary mediastinal GCTs occur in the anterior mediastinum, whereas testicular GCTs usually metastasize to the posterior mediastinum and rarely involve the anterior mediastinum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Poorly differentiated carcinoma
         </strong>
         – In most cases, extragonadal GCTs can be clearly distinguished from a poorly differentiated carcinoma based upon histopathologic evaluation. In cases where the histopathologic diagnosis is no more specific than poorly differentiated carcinoma, the question arises whether to treat the cancer as a GCT. A key issue in such cases is confirming that the neoplasm is a carcinoma and not a hematologic malignancy. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4875.html" rel="external">
          "Poorly differentiated cancer from an unknown primary site"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Poorly differentiated carcinomas with a primarily midline distribution sometimes respond dramatically to chemotherapy, similarly to GCTs. Moreover, GCTs are the only carcinomas that present in this way that are likely to be cured with chemotherapy. Therefore, a poorly differentiated carcinoma of the retroperitoneum or anterior mediastinum should generally be treated as a GCT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although serum tumor markers are commonly measured in this scenario, the results do not influence treatment since because GCT chemotherapy should be administered regardless of serum tumor marker levels. Elevated serum tumor markers are also not associated with a better outcome following such treatment [
         <a href="#rid19">
          19-22
         </a>
         ]. However, if tumor markers are elevated at baseline, they can be used to monitor response during treatment as well as detect disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of cytogenetic analysis for extra copies of chromosome arm 12p is also of limited value. Although such a finding is highly specific for a diagnosis of GCT, identification of this chromosomal abnormality has not been shown to improve outcomes [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Tumor markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extragonadal nonseminomatous GCTs are often associated with elevations in serum alpha-fetoprotein (AFP) and/or beta-human chorionic gonadotropin (beta-hCG). AFP and/or beta-hCG is elevated in 85 percent of cases of extragonadal nonseminomatous GCTs. Although an elevation in AFP excludes the diagnosis of a pure seminoma, up to 50 percent of patients with extragonadal seminoma have small to moderate increases in serum beta-hCG [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">
          "Serum tumor markers in testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
         The frequency of tumor marker abnormalities is different when mediastinal and retroperitoneal nonseminomatous GCTs are compared. Mediastinal nonseminomatous GCTs are more likely to have elevations of serum AFP but are less likely to have pronounced elevations of beta-hCG compared with gonadal and retroperitoneal nonseminomatous GCTs.
        </p>
        <p>
         This pattern of tumor markers was illustrated in one observational series of 635 patients of extragonadal GCTs [
         <a href="#rid24">
          24
         </a>
         ]. In this study, compared with retroperitoneal nonseminomatous GCTs, mediastinal nonseminomatous GCTs were associated with a higher and more frequently elevated serum AFP (median 2548 versus 25 ng/mL; 74 versus 51 percent) and a lower, less frequently elevated serum beta-hCG (median 5 versus 335 milli-international units/mL; 38 versus 74 percent).
        </p>
        <p class="headingAnchor" id="H158438">
         <span class="h1">
          MEDIASTINAL GERM CELL TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mediastinal GCTs include mature teratomas, immature teratomas, seminomas, and nonseminomatous GCTs. (See
         <a class="local">
          'Pathologic definitions'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Mature teratomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mature teratomas of the mediastinum contain well-differentiated histologic elements derived from at least two of the three embryonic cell layers (also known as the germinal layers): ectoderm, mesoderm, and endoderm  (
         <a class="graphic graphic_picture graphicRef80508" href="/z/d/graphic/80508.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef57501" href="/z/d/graphic/57501.html" rel="external">
          picture 2
         </a>
         ). Tumors containing a mixture of mature teratoma and other GCT elements (mixed tumors) should be treated as mediastinal nonseminomatous GCTs  (
         <a class="graphic graphic_table graphicRef59492" href="/z/d/graphic/59492.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors", section on 'Mature teratoma'
         </a>
         .)
        </p>
        <p>
         In males, mediastinal teratomas and testicular teratomas are distinct clinical entities. Mature teratomas of the testis are not considered benign; they have metastatic potential (although less than other testicular GCTs) and are treated in a similar manner to other testicular nonseminomatous GCTs. In contrast, mature teratomas of the mediastinum are considered benign. (See
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors", section on 'Teratoma'
         </a>
         and
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mature teratomas of the mediastinum tend to grow slowly, and as a result, they are more likely than other mediastinal GCTs to be diagnosed incidentally while they are still asymptomatic  (
         <a class="graphic graphic_diagnosticimage graphicRef78698" href="/z/d/graphic/78698.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Symptoms (chest pain, cough, dyspnea, and bronchial obstruction and postobstructive pneumonia) are generally due to compression and obstruction of surrounding organs [
         <a href="#rid26">
          26,27
         </a>
         ]. Erosion into an adjacent bronchus can rarely lead to expectoration of hair (trichoptysis) or sebaceous debris [
         <a href="#rid27">
          27
         </a>
         ]. Erosions into the pericardium, adjacent vascular structures, or through the skin to form a draining fistula are rare but serious complications [
         <a href="#rid26">
          26,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Imaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiography, whether performed incidentally or because of symptoms, typically shows an anterior mediastinal mass, with calcification reported in 26 percent of mature teratomas [
         <a href="#rid26">
          26
         </a>
         ]. In some patients, well-formed teeth or bone are seen on plain film, findings that are very suggestive of the diagnosis.
        </p>
        <p>
         Computed tomography (CT) and magnetic resonance imaging (MRI) are helpful in localizing lesions and determining the spatial relationships with surrounding structures. They can also characterize densities within the lesion suggestive of fat, sebaceous material, or cystic elements  (
         <a class="graphic graphic_diagnosticimage graphicRef78698" href="/z/d/graphic/78698.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of mature mediastinal teratomas is surgical excision, and this is almost always curative [
         <a href="#rid31">
          31,32
         </a>
         ]. Resection generally is through a median sternotomy or posterolateral thoracotomy, depending upon the location of the tumor, although thoracoscopic resection is occasionally possible [
         <a href="#rid26">
          26,33
         </a>
         ].
        </p>
        <p>
         Subtotal resection with relief of compressive symptoms is performed if benign teratomas cannot be excised completely without endangering surrounding vital structures. If only subtotal resection is possible, it is not clear that additional treatment with chemotherapy or radiation therapy (RT) offers any benefit, and observation is appropriate. Mature teratomas are relatively insensitive to both chemotherapy and RT [
         <a href="#rid26">
          26,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Immature teratomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Teratomas of the mediastinum exist on a continuum ranging from purely mature to predominantly immature  (
         <a class="graphic graphic_picture graphicRef54587" href="/z/d/graphic/54587.html" rel="external">
          picture 3
         </a>
         ). These tumors are rare enough that clinically meaningful criteria for defining immaturity are not well established. Immature teratomas are characterized by mature elements from all three germinal layers, which are mixed with immature tissue. Macroscopically, immature teratomas form cystic masses with areas of hemorrhage and necrosis. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors", section on 'Immature teratomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment for immature mediastinal teratomas is uncertain. Radical resection is indicated but is often carried out after four cycles of cisplatin-based chemotherapy with either
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (VIP  (
         <a class="graphic graphic_table graphicRef51451" href="/z/d/graphic/51451.html" rel="external">
          table 2
         </a>
         )), or
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , etoposide, and cisplatin (BEP,  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         )). Either regimen is a reasonable option. However, the benefits of chemotherapy and the optimal timing in relation to surgery have not been established in randomized trials due to the rarity of the disease. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
         Some experts prefer VIP over BEP in these patients since they generally require major thoracic surgery at the conclusion of chemotherapy and may be at risk for serious bleomycin-related postoperative pulmonary complications (eg, pneumonitis and pulmonary fibrosis) [
         <a href="#rid34">
          34
         </a>
         ]. However, other experts prefer BEP over VIP because they have not observed severe postoperative pulmonary complications in mediastinal GCT patients treated with BEP [
         <a href="#rid35">
          35
         </a>
         ], and VIP is associated with greater hematologic toxicity [
         <a href="#rid36">
          36,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">
          "Bleomycin-induced lung injury"
         </a>
         .)
        </p>
        <p>
         Although primary, immature, mediastinal teratomas in adults often have a poor prognosis, long-term survival has been reported with preoperative chemotherapy and aggressive surgical resection [
         <a href="#rid38">
          38
         </a>
         ]. Immature teratomas containing elements of other GCTs should be treated like other mediastinal nonseminomatous GCTs, ie, with four cycles of VIP or BEP chemotherapy followed by resection of any residual disease. (See
         <a class="local">
          'Mediastinal nonseminomatous GCTs'
         </a>
         below.)
        </p>
        <p>
         If secondary somatic malignant differentiation (ie, teratoma with malignant transformation) is present without other GCT elements, resection is the treatment of choice. When resection is possible, the outcome is similar to other patients with teratoma. However, if these tumors are unresectable or have metastasized, they are generally incurable. If the transformation is limited to a single cell type, tailored chemotherapy directed towards that cell type may result in major responses and even long-term survival in selected patients [
         <a href="#rid39">
          39
         </a>
         ], but it is unclear whether such tailored chemotherapy is more effective than standard GCT chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors", section on 'Teratoma with somatic-type malignancy'
         </a>
         .)
        </p>
        <p>
         In children, immature mediastinal teratomas behave similarly to mature teratomas (ie, as benign tumors) and should be completely excised. (See
         <a class="local">
          'Mature teratomas'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Mediastinal seminoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mediastinal seminomas constitute approximately one-third of malignant mediastinal GCTs and 2 to 4 percent of mediastinal masses  (
         <a class="graphic graphic_picture graphicRef66422 graphicRef54661" href="/z/d/graphic/66422.html" rel="external">
          picture 4A-B
         </a>
         ) [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors", section on 'Seminomas'
         </a>
         .)
        </p>
        <p>
         Mediastinal seminomas occur predominantly in males between the ages of 20 and 40 [
         <a href="#rid31">
          31
         </a>
         ]. Although it is uncommon for testicular seminoma to metastasize to the mediastinum in the absence of retroperitoneal lymph node involvement [
         <a href="#rid18">
          18
         </a>
         ], all males with mediastinal seminoma should undergo careful testicular palpation and ultrasonography. Orchiectomy is generally indicated in the event of suspicious findings. Mediastinal dysgerminomas (the female counterpart to seminomas) are rare in females with histologically normal ovaries.
        </p>
        <p>
         In order for a GCT to be classified as a seminoma in males or a dysgerminoma in females, no other histologic element of a GCT can be present, and serum alpha-fetoprotein (AFP) must be normal (unless liver disease or another medical condition exists to explain the AFP elevation)  (
         <a class="graphic graphic_picture graphicRef66422 graphicRef54661" href="/z/d/graphic/66422.html" rel="external">
          picture 4A-B
         </a>
         ). Tumors consisting of a mixture of seminoma and other tumor types are termed mixed GCTs and are treated as nonseminomatous GCTs. (See
         <a class="local">
          'Mediastinal nonseminomatous GCTs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Clinical manifestations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         – Primary mediastinal seminomas are typically slow growing and can be very bulky by the time they cause discomfort. The majority (75 percent) are symptomatic at the time of diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The common presenting symptoms are illustrated by a series of 52 patients with mediastinal seminoma [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chest pain – 39 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dyspnea – 29 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cough – 22 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Weight loss – 19 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Superior vena cava syndrome – 12 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fever – 6 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nausea – 6 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor markers
         </strong>
         – Serum beta-human chorionic gonadotropin (beta-hCG) is elevated in approximately one-third of patients [
         <a href="#rid24">
          24
         </a>
         ]. However, such elevations are typically modest in mediastinal seminomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Very highly elevated beta-hCG levels (greater than 1000 or 5000 IU/L) may indicate the presence of nonseminomatous GCT elements. Although data are limited for a specific cutoff level, we generally treat tumors with a beta-hCG &gt;5000 IU/L as a nonseminomatous GCT because these tumor marker levels are almost always seen in tumors where choriocarcinoma or embryonal carcinoma have been reported on histopathology. This issue is more problematic for mediastinal seminomas than testicular seminomas because the histopathological diagnosis is typically based on a core biopsy rather than resection of the entire primary tumor (orchiectomy) where the tumor can be more completely examined. The risk of a sampling error and missing nonseminomatous elements is thus greater for mediastinal tumors. (See
         <a class="local">
          'Tumor markers'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">
          "Serum tumor markers in testicular germ cell tumors", section on 'False-positive hCG'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Seminomas do not produce AFP. An elevated serum AFP is inconsistent with the diagnosis of a pure seminoma and indicates that nonseminomatous elements are present, even if the histopathologic diagnosis is pure seminoma. Such tumors are treated as nonseminomatous GCTs. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sites of metastatic disease
         </strong>
         – The majority of mediastinal seminomas have metastasized by the time they are detected, most often to the lymph nodes and less commonly to lungs, bone, and/or liver [
         <a href="#rid24">
          24
         </a>
         ]. Detection of extramediastinal spread is important because the presence of nonpulmonary visceral metastases is associated with a poorer prognosis. CT imaging is essential to evaluate the primary tumor, retroperitoneal lymph nodes, and liver. The presence of retroperitoneal lymphadenopathy is uncommon in the setting of primary mediastinal seminoma and may be more suggestive of a testicular or retroperitoneal primary tumor.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seminomas are exquisitely sensitive to both cisplatin-based chemotherapy and RT, regardless of location. The relative merits of chemotherapy, RT, and surgery have not been evaluated in randomized trials, and treatment recommendations are based largely upon observational studies and extrapolated from the treatment of advanced testicular seminomas [
         <a href="#rid24">
          24,41
         </a>
         ].
        </p>
        <p>
         Males with mediastinal seminomas without evidence of nonpulmonary organ metastases are classified as good-risk GCTs by the International Germ Cell Consensus Classification (IGCCC) and have a five-year survival rate of more than 90 percent [
         <a href="#rid41">
          41,42
         </a>
         ]. Most centers prefer chemotherapy to RT for patients with mediastinal seminoma, even when disease is limited to the mediastinum. Retrospective data show improved progression-free survival with cisplatin-based chemotherapy, and there is an increased risk of cardiovascular events, secondary malignancies, and other toxicity following mediastinal RT [
         <a href="#rid24">
          24,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h4">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mediastinal seminomas and no metastases to organs other than the lungs, chemotherapy regimens that are widely used are three cycles of BEP chemotherapy  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         ) or four cycles of
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (EP) without
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">
          table 4
         </a>
         ). These regimens are similar to those used to treat advanced testicular seminoma. In patients who have previously received RT to the chest or mediastinum, who have underlying lung disease, or who are older than 50 years of age, the EP regimen  (
         <a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">
          table 4
         </a>
         ) is preferred due to an increased risk of bleomycin lung toxicity [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Good risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">
          "Bleomycin-induced lung injury", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
         Patients with mediastinal seminoma and metastases to the liver, bones, or other nonpulmonary organs should be treated with four cycles of BEP chemotherapy  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         ). Patients with metastases to organs other than the lungs who cannot tolerate
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         should receive four courses of VIP  (
         <a class="graphic graphic_table graphicRef51451" href="/z/d/graphic/51451.html" rel="external">
          table 2
         </a>
         ). As noted above, for patients who have received RT to the chest or mediastinum or have underlying lung disease or who are over 50 years of age, we typically use a bleomycin-free regimen [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Cisplatin-based chemotherapy was evaluated in an observational series of 635 patients with extragonadal GCTs [
         <a href="#rid24">
          24
         </a>
         ]. This study included a subgroup of 103 patients with either mediastinal or retroperitoneal seminomas who were treated with either chemotherapy (75 percent), RT (6 percent), or a combination of chemotherapy and RT (19 percent). For the patients with mediastinal and retroperitoneal seminomas, five-year progression-free survival was 88 and 77 percent respectively; five-year overall survival was 88 percent for both groups. Among the patients with seminomas, chemotherapy was associated with a higher five-year progression-free survival compared with RT, although the small number of patients treated with radiation (n = 3) limits the reliability of these data [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="local">
          'Residual mass'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h4">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In those rare patients who are not candidates for chemotherapy, primary RT (35 to 50 Gy) is an acceptable alternative strategy in the absence of bulky or metastatic disease [
         <a href="#rid25">
          25
         </a>
         ]. If RT is used, the radiation portals should include the mediastinum and bilateral supraclavicular fossae. Careful treatment planning is essential to avoid unnecessary toxicity to the lungs, heart, and other surrounding tissues.
        </p>
        <p>
         Mediastinal radiation has been associated with coronary artery disease, valvular heart disease, diastolic dysfunction, and constrictive pericarditis. In addition, an increased frequency of late breast, esophageal, and lung cancers, as well as other malignancies, has been reported. (See
         <a class="medical medical_review" href="/z/d/html/7062.html" rel="external">
          "Cardiotoxicity of radiation therapy for breast cancer and other malignancies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h4">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, surgical resection or debulking plays no role in the initial management of seminomas because of the typical presence of bulky and/or metastatic disease [
         <a href="#rid24">
          24
         </a>
         ]. Complete surgical excision may be performed in the unusual case in which a mediastinal seminoma is discovered when very small and localized. Adjuvant therapy is not typically required for such small lesions that are discovered incidentally or surgically resected before a diagnosis is made.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h4">
          Residual mass
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following chemotherapy, many patients are left with a residual mass. Most of these masses are benign and consist of necrosis or a scirrhous or desmoplastic reaction. Residual masses ≥3 cm in diameter may contain residual malignancy in up to 30 percent of cases, based on data from testicular seminoma with metastatic adenopathy postchemotherapy [
         <a href="#rid44">
          44-46
         </a>
         ]. However, unless there is histologic confirmation of residual disease, residual masses should
         <strong>
          not
         </strong>
         be empirically treated with chemotherapy or RT based on size alone, which is not always associated with the presence of viable seminoma [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
         The optimal treatment of a residual mass is a subject of contention, and our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumors &lt;3 cm
         </strong>
         – We offer surveillance for residual masses &lt;3 cm. Surgical resection is often technically difficult and may be unnecessary for such masses. [
         <a href="#rid44">
          44-46
         </a>
         ]. The surveillance schedule is similar to that of patients with testicular seminoma who are treated with chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">
          "Posttreatment follow-up for testicular germ cell tumors", section on 'Seminoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumors ≥3 cm
         </strong>
         – For residual masses ≥3 cm, we evaluate with a positron emission tomography (PET)-CT scan at least six weeks or more after completing chemotherapy. PET-negative lesions should be observed. Strongly PET-positive lesions require histopathological documentation of residual cancer by biopsy or resection. Borderline PET-positive lesions can be followed with either additional PET-CT or CT imaging in six to eight weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatives to PET-CT imaging include an open biopsy or close observation using periodic contrast-enhanced CT scans [
         <a href="#rid44">
          44,46
         </a>
         ]. One surveillance regimen that has been used is CT imaging every three months for the first year and every six months for the second year or until normal. Further therapeutic intervention for patients undergoing surveillance is performed only for progressive disease [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If PET-CT is utilized, it should be obtained at least six weeks after completion of chemotherapy to avoid a potential false-positive result due to treatment-related inflammation. Data suggest that PET imaging with fluorodeoxyglucose contrast performed after chemotherapy is highly accurate in distinguishing benign from malignant residual masses [
         <a href="#rid46">
          46,49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, a positive PET-CT scan alone is not strong enough evidence to justify additional treatment with chemotherapy or RT, due to a significant false-positive rate, and suspicious PET-positive masses must undergo tissue sampling.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a patient with a residual mass larger than 3 cm for whom a resection or open biopsy is planned, a negative PET scan provides a reasonable basis for foregoing these procedures, unless the mass is increasing in size. In observational studies, the false-negative rate for PET imaging in masses over 3 cm in size has been reported to be zero [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients who have histologically confirmed, residual, viable malignancy or who develop progressive disease should generally be treated with salvage chemotherapy. RT represents an alternative approach for selected patients (eg, those in whom additional chemotherapy is not possible). (See
         <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">
          "Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H158872">
         <span class="h4">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term disease-free survival (DFS) is achieved in roughly 90 percent of patients treated with chemotherapy [
         <a href="#rid24">
          24
         </a>
         ]. Although most patients treated with primary RT are cured, the distant relapse rate is high, and the five-year DFS rate is only 60 to 67 percent [
         <a href="#rid24">
          24,51
         </a>
         ]. Most patients who relapse following primary RT can be salvaged with chemotherapy, but there is some evidence that the overall survival rate may be higher with initial chemotherapy [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Unlike patients with mediastinal nonseminomatous GCTs, mediastinal seminomas are not associated with secondary malignant differentiation into non-germ-cell malignancies [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="local">
          'Association with other malignancies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Mediastinal nonseminomatous GCTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonseminomatous germ cell tumors (GCTs) of the mediastinum contain yolk sac tumor, choriocarcinoma, and/or embryonal carcinoma. Mixed GCTs may contain more than one cell type, as well as elements of teratoma and/or seminoma. Tumors that consist of a mixture of seminoma and teratoma are considered nonseminomatous GCTs. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors", section on 'Nonseminomatous GCTs'
         </a>
         .)
        </p>
        <p>
         In contrast to gonadal and retroperitoneal nonseminomatous GCTs, mediastinal nonseminomatous GCTs contain embryonal carcinoma less frequently, whereas yolk sac tumors (either pure or mixed with other histologies) are common  (
         <a class="graphic graphic_picture graphicRef78211" href="/z/d/graphic/78211.html" rel="external">
          picture 5
         </a>
         ). In one series of 64 cases, 60 percent were pure yolk sac tumors, 12 percent were pure choriocarcinomas, and 9 percent were pure embryonal carcinomas [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Mediastinal nonseminomatous GCTs occur far more often in males than in females and usually are diagnosed between the ages of 20 and 40 years. Patients with mediastinal nonseminomatous GCTs are also at risk for developing fatal hematologic disorders. These typically display a megakaryocytic lineage and share cytogenetic abnormalities with nonseminomatous GCTs. (See
         <a class="local">
          'Association with other malignancies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with mediastinal nonseminomatous GCTs are symptomatic at presentation [
         <a href="#rid54">
          54,55
         </a>
         ]. Signs and symptoms may include fever, chills, weight loss, chest pain, dyspnea, and/or superior vena cava syndrome. Gynecomastia can be seen in tumors with foci of choriocarcinoma that secrete large amounts of hCG. (See
         <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">
          "Clinical features, diagnosis, and evaluation of gynecomastia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1184708546">
         <span class="h3">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients have an elevated serum AFP at presentation, and a sizable minority have an elevated serum beta-hCG. This pattern is so characteristic that some institutions accept elevated AFP and beta-hCG in a young adult male with an anterior mediastinal mass as de facto evidence of an extragonadal nonseminomatous GCT, and chemotherapy is sometimes started without a tissue diagnosis.
        </p>
        <p>
         However, we recommend histologic confirmation in all patients if it can be safely accomplished, unless the clinical scenario demands immediate treatment. Histologic confirmation is clearly required in the roughly 10 percent of patients with normal serum tumor markers.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mediastinal nonseminomatous GCTs are aggressive tumors that are often metastatic at presentation [
         <a href="#rid54">
          54,56
         </a>
         ]. A multimodality approach is generally used, utilizing chemotherapy initially, followed by surgery to resect any residual masses.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h4">
          Systemic chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary mediastinal nonseminomas are classified as poor risk by the IGCCC. Initial treatment consists of four cycles of cisplatin-based chemotherapy as is used in patients with poor-risk advanced, testicular GCTs. The standard regimens used are either VIP  (
         <a class="graphic graphic_table graphicRef51451" href="/z/d/graphic/51451.html" rel="external">
          table 2
         </a>
         ) or BEP  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         ). Further details on studies that compare these regimens in patients with advanced nonseminomatous GCTs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Intermediate- and poor-risk advanced disease'
         </a>
         .)
        </p>
        <p>
         The efficacy of VIP compared with BEP appears to be similar, so the choice of therapy is based on clinician preference and the ability to monitor or minimize the risk for
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         toxicity. Four cycles of VIP are preferred by some oncologists for primary mediastinal nonseminomas because these patients will typically undergo a thoracotomy or sternotomy for resection of residual disease. This may require prolonged exposure to high partial pressures of oxygen during surgery, which can provoke bleomycin-related pneumonitis. However, we are also comfortable treating patients with BEP if other risk factors for bleomycin pulmonary toxicity are absent and if serial pulmonary function tests are obtained to monitor diffusing capacity for carbon monoxide and vital capacity. To minimize postoperative risks in all patients previously treated with BEP, including those with mediastinal nonseminomas, we limit the excessive use of both supplemental oxygen and intravenous fluid support. (See
         <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">
          "Bleomycin-induced lung injury"
         </a>
         .)
        </p>
        <p>
         Data supporting the use of the VIP regimen comes from a retrospective series of 221 patients who underwent thoracic surgery at Indiana University following chemotherapy [
         <a href="#rid34">
          34
         </a>
         ]. In this series, 22 of 166 patients treated with BEP developed acute respiratory distress syndrome (13 percent) versus 0 of 55 treated with VIP; prolonged ventilator use was required in 30 (18 percent) of those treated with BEP versus 2 (4 percent) of those treated with VIP. There were 11 perioperative deaths (7 percent) with BEP, 10 of which were secondary to pulmonary failure, versus no deaths in those treated with VIP. However, in another observational series from Memorial Sloan-Kettering Cancer Center, there was no significant difference in pulmonary complications among patients with primary mediastinal nonseminomas treated with or without
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         [
         <a href="#rid35">
          35
         </a>
         ]. In addition, no fatal pulmonary complications were observed.
        </p>
        <p>
         As with other poor-risk GCTs, early changes in the tumor markers after the first dose of therapy can be used to individualize therapy, as shown by results of the Groupe d'Etude des Tumeurs Uro-Genital (GETUG)-13 trial [
         <a href="#rid57">
          57,58
         </a>
         ]. However, longer follow-up is required before incorporating this approach into standard practice. The results of this trial are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Intermediate- and poor-risk advanced disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h4">
          Surgery for residual mass
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with mediastinal nonseminomatous GCTs have residual masses at the conclusion of chemotherapy. Resection of all residual masses following chemotherapy plays an integral role in the treatment of these tumors and should be performed whenever technically feasible [
         <a href="#rid59">
          59
         </a>
         ]. Surgery should also be offered to patients whose serum tumor markers are rising at the completion of chemotherapy, given the poor results with salvage chemotherapy [
         <a href="#rid24">
          24,60-63
         </a>
         ]. Given the complexity of these surgeries, referral to a thoracic surgeon with experience with mediastinal nonseminomas is advisable.
        </p>
        <p>
         Following postchemotherapy surgery, no further therapy is necessary if the residual masses contain teratoma or necrosis. If viable malignancy is identified, two additional cycles of chemotherapy should be given. If a patient received four cycles of VIP prior to surgery, we offer an additional two cycles of VIP as adjuvant chemotherapy. If the patient received four cycles of BEP before their operation, we offer adjuvant chemotherapy with two cycles of either EP or VIP.
        </p>
        <p class="headingAnchor" id="H3964289422">
         <span class="h4">
          Monitoring tumor markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serial monitoring of serum AFP and beta-hCG is helpful in monitoring the response to therapy and detecting early recurrence. The suggested schedule is similar to that used in testicular nonseminomatous GCTs. (See
         <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">
          "Serum tumor markers in testicular germ cell tumors", section on 'Monitoring response to therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h4">
          Treatment after relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, further systemic treatment with either standard- or high-dose chemotherapy regimens is minimally effective for patients with mediastinal nonseminomatous GCTs who relapse after cisplatin-based therapy, with DFS rates of less than 12 percent. However, subsequent reports evaluating high-dose chemotherapy have been a little more favorable, with long-term DFS of up to 25 percent with this approach [
         <a href="#rid24">
          24,56,62,64-69
         </a>
         ]. Further details on the treatment or relapsed and refractory GCTs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">
          "Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
         As an example, a retrospective review of 79 patients treated at 11 centers reported that only 8 percent of the cohort were long-term survivors, compared with 30 percent who were initially diagnosed with primary retroperitoneal disease [
         <a href="#rid24">
          24,67
         </a>
         ]. Of the 25 patients with primary mediastinal tumors who received high-dose chemotherapy with autologous stem cell transplantation at relapse, only 3 (12 percent) were long-term survivors. In subsequent observational series evaluating high-dose chemotherapy, 20 to 25 percent of patients with primary mediastinal nonseminomas achieved long-term DFS [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H158279">
         <span class="h3">
          Association with other malignancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematologic and somatic malignancies can arise in patients with mediastinal seminomatous GCTs. Further details on other subsequent malignancies in patients with testicular GCTs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">
          "Approach to the care of long-term testicular cancer survivors", section on 'Secondary malignancies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">
          "Treatment-related toxicity in testicular germ cell tumors", section on 'Second malignancies'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic malignancies
         </strong>
         – Patients with mediastinal nonseminomatous GCTs have a relatively high incidence of hematologic disorders unrelated to their prior cytotoxic chemotherapy. These include acute megakaryoblastic and myelogenous leukemia, myelodysplasia, malignant mastocytosis, and malignant histiocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one observational series of patients with primary mediastinal nonseminomatous GCTs, approximately 6 percent subsequently developed a hematologic disorder [
         <a href="#rid53">
          53
         </a>
         ]. The median time to onset of the hematologic disorder was six months, the median survival following diagnosis was five months, and no patient survived more than two years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hematologic malignancies associated with mediastinal GCTs may originate from a yolk sac, tumor-derived progenitor cell that can undergo hematopoietic differentiation and subsequently home to the bone marrow. In many cases, the malignant cells in these hematologic disorders have an isochromosome 12p or other evidence of derivation from the GCT [
         <a href="#rid53">
          53,70,71
         </a>
         ]. In one report of six patients with mediastinal GCTs associated with hematologic malignancy, four had hematopoietic precursor cells within the yolk sac component of the tumor, which had a similar morphology and immunohistochemical profile as the leukemic cells in bone marrow [
         <a href="#rid72">
          72
         </a>
         ]. Another biological study suggested that the GCT and the hematologic malignancy derive from a common precursor with parallel clonal evolution, rather than the hematologic malignancy developing directly from the differentiated GCT [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Somatic malignancy
         </strong>
         – Mediastinal nonseminomatous GCTs, particularly those with teratomatous elements, can transform into sarcomas and carcinomas that are highly resistant to treatment with chemotherapy or RT. These tumors should be resected if possible [
         <a href="#rid74">
          74,75
         </a>
         ]. Sarcomas are the predominant secondary somatic malignancy for patients with primary mediastinal nonseminoma and multiple histologies (multiple sarcomas or sarcoma plus carcinoma) can sometimes be observed. Further details on somatic malignancies that arise in nonseminomatous GCTs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4613.html" rel="external">
          "Pathology of mediastinal tumors", section on 'Nonseminomatous GCTs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H159015">
         <span class="h3">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mediastinal nonseminomatous GCTs are always considered poor-risk GCTs. These tumors carry a distinctly worse prognosis than seminomas or teratomas [
         <a href="#rid76">
          76
         </a>
         ], with a five-year overall survival rate of about 40 to 45 percent [
         <a href="#rid24">
          24,42,77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Definition of risk'
         </a>
         .)
        </p>
        <p>
         Our understanding is evolving of the underlying biologic basis for the increased aggressiveness and poor prognosis of mediastinal nonseminomas.
         <em>
          TP53
         </em>
         alterations are present in approximately 70 percent of these patients as compared with only 4 percent of those with testicular nonseminomas [
         <a href="#rid78">
          78
         </a>
         ]. Furthermore, nearly all GCT patients (gonadal or extragonadal) with
         <em>
          TP53
         </em>
         alterations who required chemotherapy have been noted to have cisplatin-resistant disease. In observational studies,
         <em>
          TP53
         </em>
         alterations and chromosome 3p25.3 gain (a separate molecular alteration also associated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         resistance in GCTs) have been associated with a poor prognosis [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
         The effectiveness of a combined-modality approach as the initial approach to treating mediastinal nonseminomatous GCTs was illustrated in a retrospective multicenter study that included 287 patients with mediastinal nonseminomatous GCTs, in which 278 patients (97 percent) were initially treated with chemotherapy [
         <a href="#rid24">
          24
         </a>
         ]. The complete response rate to chemotherapy was 19 percent, and partial response with normalization of tumor markers was observed in 45 percent. Surgery was used to resect a residual mass in 143 patients (50 percent). The five-year progression-free and overall survival rates were 44 and 45 percent, respectively.
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          RETROPERITONEAL GERM CELL TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retroperitoneal GCTs are generally bulky at the time of diagnosis because they usually are diagnosed as a result of symptoms. Their clinical behavior, prognosis, and management are similar to disseminated testicular GCTs [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of testicular germ cell tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Retroperitoneal seminoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a retroperitoneal seminoma, systemic chemotherapy with a cisplatin-based regimen is the preferred approach, using the same regimens as for patients with advanced testicular seminoma. (See
         <a class="medical medical_review" href="/z/d/html/2990.html" rel="external">
          "Treatment of stage II seminoma", section on 'Stage IIC seminoma'
         </a>
         .)
        </p>
        <p>
         The results with this approach are similar to those for advanced testicular seminoma. In a multinational series that included 52 patients with retroperitoneal seminoma and 51 with mediastinal seminoma, the progression-free and overall five-year survival rates for the entire cohort were 87 and 90 percent, respectively [
         <a href="#rid24">
          24,41
         </a>
         ]. In this series, 75 percent of patients were treated with chemotherapy alone. (See
         <a class="medical medical_review" href="/z/d/html/2990.html" rel="external">
          "Treatment of stage II seminoma"
         </a>
         .)
        </p>
        <p>
         Nonbulky retroperitoneal seminomas can also be treated with primary radiation therapy (RT) in a manner similar to stage II testicular seminoma. However, there is insufficient published experience to determine the complete remission and cure rates using this approach. (See
         <a class="medical medical_review" href="/z/d/html/2990.html" rel="external">
          "Treatment of stage II seminoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Retroperitoneal nonseminomatous GCTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial therapy of patients with retroperitoneal nonseminomatous germ cell tumors (GCTs) consists of either three or four cycles of cisplatin-based chemotherapy, depending upon whether the patient falls into the good- or intermediate/poor-prognosis group. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
         The results with this approach are illustrated by a multicenter series of 227 patients with retroperitoneal nonseminomatous GCTs, of whom 98 percent were treated with chemotherapy initially [
         <a href="#rid24">
          24
         </a>
         ]. Of these, 101 (45 percent) underwent surgery for resection of a residual mass. The five-year progression-free and overall survival rates were 42 and 65 percent, respectively.
        </p>
        <p>
         For those who relapse following first-line chemotherapy, salvage cisplatin-based chemotherapy is identical to that for gonadal nonseminomatous GCTs. In one large review, 30 percent of patients with relapsed retroperitoneal nonseminomatous GCTs achieved long-term disease-free survival (DFS) [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">
          "Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H159138">
         <span class="h2">
          Retroperitoneal teratomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pure teratomas of the retroperitoneum are rare, and they are generally treated with complete surgical resection as the primary therapy [
         <a href="#rid82">
          82-84
         </a>
         ]. Because the preoperative diagnosis is based on a needle or open biopsy, it is possible that complete resection will reveal the presence of nonteratoma GCT elements. In such cases, when the amount of viable GCT is small, two cycles of adjuvant chemotherapy is sufficient, typically with
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (EP). Although data are limited to guide management, when more substantial amounts of viable GCT are present (pN3), options include three cycles of
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , etoposide, and cisplatin (BEP  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         )) or four cycles of EP  (
         <a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">
          table 4
         </a>
         ), using a similar approach to good-risk testicular GCTs. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H806436949">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122274.html" rel="external">
          "Society guideline links: Testicular cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extragonadal germ cell tumors
         </strong>
         – Extragonadal germ cell tumors (GCTs) are rare tumors that most frequently arise in the mediastinum and retroperitoneum in adult males. (See
         <a class="local">
          'Pathologic definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mature mediastinal teratomas
         </strong>
         – Patients with a mature teratoma of the mediastinum are treated with complete surgical resection. Partial resection should be limited to patients in whom a complete resection is not technically feasible. Mature teratomas are relatively insensitive to both chemotherapy and radiation therapy (RT). (See
         <a class="local">
          'Mature teratomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immature mediastinal teratomas
         </strong>
         – For patients with immature teratomas of the mediastinum, we suggest four cycles of cisplatin-based chemotherapy followed by complete surgical resection, if technically feasible, rather than initial surgery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Immature teratomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemotherapy options include four cycles of
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (VIP  (
         <a class="graphic graphic_table graphicRef51451" href="/z/d/graphic/51451.html" rel="external">
          table 2
         </a>
         )) or
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , etoposide, and cisplatin (BEP  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         )). For patients treated with BEP, we closely monitor pulmonary function tests due to the potential for postoperative pulmonary complications at thoracic surgery following chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">
          "Bleomycin-induced lung injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mediastinal seminomas
         </strong>
         – For patients with a mediastinal seminoma, we suggest cisplatin-based chemotherapy rather than RT or surgery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Mediastinal seminoma'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Good-risk patients are generally treated with three cycles of BEP  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         ) or four cycles of
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (EP  (
         <a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">
          table 4
         </a>
         )).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intermediate-risk patients (ie, those with nonpulmonary visceral metastases) should receive four cycles of BEP or VIP  (
         <a class="graphic graphic_table graphicRef51451" href="/z/d/graphic/51451.html" rel="external">
          table 2
         </a>
         ) chemotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RT is an alternative for patients who do not have bulky or metastatic disease and for whom there are contraindications to cisplatin-based GCT chemotherapy regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mediastinal seminomas that also contain elements of other cell types or those with an elevation of serum alpha-fetoprotein (AFP) are nonseminomatous GCTs and should be treated as such. (See
         <a class="local">
          'Mediastinal nonseminomatous GCTs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Residual masses after chemotherapy for mediastinal seminoma
         </strong>
         – For patients with mediastinal seminomas treated with chemotherapy who are left with a residual mass, our treatment approach is based upon the size of the residual mass. (See
         <a class="local">
          'Residual mass'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For residual masses &lt;3 cm, we offer surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For residual masses ≥3 cm, we evaluate with a positron emission tomography (PET)-CT scan at least six weeks or more after completing chemotherapy. PET-negative lesions should be observed. Strongly PET-positive lesions require histopathological documentation of residual cancer by biopsy or resection. Borderline PET-positive lesions can be followed with either additional PET-CT or CT imaging in six to eight weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Alternatives to PET-CT imaging include an open biopsy or close observation using periodic contrast-enhanced CT scans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mediastinal nonseminomatous GCTs
         </strong>
         – For patients with a mediastinal nonseminomatous GCT, we suggest initial treatment with four cycles of cisplatin-based chemotherapy, rather than surgery or RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemotherapy options include VIP  (
         <a class="graphic graphic_table graphicRef51451" href="/z/d/graphic/51451.html" rel="external">
          table 2
         </a>
         ) or BEP  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 3
         </a>
         ). For patients treated with BEP, we closely monitor pulmonary function due to the potential for postoperative pulmonary complications at thoracic surgery following chemotherapy. (See
         <a class="local">
          'Mediastinal nonseminomatous GCTs'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">
          "Bleomycin-induced lung injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a residual mediastinal mass following initial chemotherapy, we recommend complete surgical resection, if technically feasible (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). If viable malignancy is identified, we suggest two additional cycles of cisplatin-based chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Surgery for residual mass'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retroperitoneal seminoma
         </strong>
         – For patients with a retroperitoneal seminoma, we suggest cisplatin-based chemotherapy using the same regimens as used for patients with advanced testicular seminoma rather than RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). RT may be an alternative for patients with nonbulky disease. (See
         <a class="local">
          'Retroperitoneal seminoma'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2990.html" rel="external">
          "Treatment of stage II seminoma", section on 'Stage IIC seminoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retroperitoneal nonseminomatous GCTs
         </strong>
         – For patients with a retroperitoneal nonseminomatous GCT, we suggest cisplatin-based chemotherapy as would be used for a testicular nonseminomatous GCT, rather than RT or surgery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Depending upon whether the patient falls into the good- or intermediate/poor-prognosis group, this would include three or four cycles of treatment. This should be followed by surgical resection of any residual mass. (See
         <a class="local">
          'Retroperitoneal nonseminomatous GCTs'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2992.html" rel="external">
          "Retroperitoneal lymph node dissection for early-stage testicular germ cell tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1494842047">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Philip W Kantoff, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Wick MR, Perlman EJ, Orazi A, Muller-Hermelink HK. Germ cell tumours of the mediastinum. In: Tumours of the Lung, Pleura, Thymus and Heart, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 2006; 24:2544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenney JK, Heerema-McKenney A, Rouse RV. Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol 2007; 14:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glenn OA, Barkovich AJ. Intracranial germ cell tumors: a comprehensive review of proposed embryologic derivation. Pediatr Neurosurg 1996; 24:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000; 60:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hailemariam S, Engeler DS, Bannwart F, Amin MB. Primary mediastinal germ cell tumor with intratubular germ cell neoplasia of the testis--further support for germ cell origin of these tumors: a case report. Cancer 1997; 79:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaganti RS, Rodriguez E, Mathew S. Origin of adult male mediastinal germ-cell tumours. Lancet 1994; 343:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busch J, Seidel C, Zengerling F. Male Extragonadal Germ Cell Tumors of the Adult. Oncol Res Treat 2016; 39:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daugaard G, Rørth M, von der Maase H, Skakkebaek NE. Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies. Ann Oncol 1992; 3:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann JT, Fossa SD, Nichols CR, et al. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 2001; 93:1733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguirre D, Nieto K, Lazos M, et al. Extragonadal germ cell tumors are often associated with Klinefelter syndrome. Hum Pathol 2006; 37:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Völkl TM, Langer T, Aigner T, et al. Klinefelter syndrome and mediastinal germ cell tumors. Am J Med Genet A 2006; 140:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams LA, Pankratz N, Lane J, et al. Klinefelter syndrome in males with germ cell tumors: A report from the Children's Oncology Group. Cancer 2018; 124:3900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonouvrie K, van der Werff Ten Bosch J, van den Akker M. Klinefelter syndrome and germ cell tumors: review of the literature. Int J Pediatr Endocrinol 2020; 2020:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comiter CV, Renshaw AA, Benson CB, Loughlin KR. Burned-out primary testicular cancer: sonographic and pathological characteristics. J Urol 1996; 156:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balzer BL, Ulbright TM. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases. Am J Surg Pathol 2006; 30:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böhle A, Studer UE, Sonntag RW, Scheidegger JR. Primary or secondary extragonadal germ cell tumors? J Urol 1986; 135:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Currow DC, Findlay M, Cox K, Harnett PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer 1996; 32A:2357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavlidis N, Kalef-Ezra J, Briassoulis E, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 1994; 22:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yonemori K, Ando M, Shibata T, et al. Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Cancer Res Clin Oncol 2006; 132:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Rodriguez E, Reuter VE, et al. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995; 13:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20:1864.
          </a>
         </li>
         <li class="breakAll">
          Cameron RB, Loehrer PJ, Thomas CR. Neoplasms of the mediastinum. In: Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenber SA (Eds), Lippincott Williams &amp; Wilkins, New York 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis BD, Hurt RD, Payne WS, et al. Benign teratomas of the mediastinum. J Thorac Cardiovasc Surg 1983; 86:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adebonojo SA, Nicola ML. Teratoid tumors of the mediastinum. Am Surg 1976; 42:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunes S, Varon J, Walsh G. Mediastinal teratoma presenting as massive hemoptysis in an adult. J Emerg Med 1997; 15:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polansky SM, Barwick KW, Ravin CE. Primary mediastinal seminoma. AJR Am J Roentgenol 1979; 132:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moeller KH, Rosado-de-Christenson ML, Templeton PA. Mediastinal mature teratoma: imaging features. AJR Am J Roentgenol 1997; 169:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dulmet EM, Macchiarini P, Suc B, Verley JM. Germ cell tumors of the mediastinum. A 30-year experience. Cancer 1993; 72:1894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeda S, Miyoshi S, Ohta M, et al. Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution. Cancer 2003; 97:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feo CF, Chironi G, Porcu A, et al. Videothoracoscopic removal of a mediastinal teratoma. Am Surg 1997; 63:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranganath P, Kesler KA, Einhorn LH. Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor. J Clin Oncol 2016; 34:4445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caso R, Jones GD, Bains MS, et al. Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. Ann Surg 2021; 274:e1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003; 97:1869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai K, Ohta S, Suzuki M, Suzuki H. Primary immature mediastinal teratoma in adulthood. Eur J Surg Oncol 1997; 23:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003; 21:4285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S, Przygodzki RM, Koss MN. Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases. Cancer 1997; 80:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bokemeyer C, Droz JP, Horwich A, et al. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer 2001; 91:1394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuels ML, Johnson DE, Holoye PY, Lanzotti VJ. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA 1976; 235:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultz SM, Einhorn LH, Conces DJ Jr, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989; 7:1497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer R, Bosl G, Heelan R, et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987; 5:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996; 14:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwich A, Paluchowska B, Norman A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997; 8:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997; 33:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19:3740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinz S, Schrader M, Kempkensteffen C, et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol 2008; 179:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hainsworth JD, Greco FA. Extragonadal germ cell tumors and unrecognized germ cell tumors. Semin Oncol 1992; 19:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain KK, Bosl GJ, Bains MS, et al. The treatment of extragonadal seminoma. J Clin Oncol 1984; 2:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann JT, Nichols CR, Droz JP, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 2000; 92:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S, Koss MN. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases. Cancer 1997; 80:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knapp RH, Hurt RD, Payne WS, et al. Malignant germ cell tumors of the mediastinum. J Thorac Cardiovasc Surg 1985; 89:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fizazi K, Culine S, Droz JP, et al. Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 1998; 16:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014; 15:1442.
          </a>
         </li>
         <li class="breakAll">
          Fizazi K, Flechon A, Le Teuff G, et al. Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). Abstract 4504, 2016 American Society Of Clinical Oncology meeting.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang TH, Hung GY, Weng TF, et al. Surgical treatment confers prognostic significance in pediatric malignant mediastinal germ cell tumors. Cancer 2022; 128:4139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vuky J, Bains M, Bacik J, et al. Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 2001; 19:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radaideh SM, Cook VC, Kesler KA, Einhorn LH. Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy. Ann Oncol 2010; 21:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganjoo KN, Rieger KM, Kesler KA, et al. Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. Cancer 2000; 88:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider BP, Kesler KA, Brooks JA, et al. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. J Clin Oncol 2004; 22:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hidalgo M, Paz-Ares L, Rivera F, et al. Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol 1997; 8:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broun ER, Nichols CR, Einhorn LH, Tricot GJ. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 1991; 68:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 1994; 12:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann JT, Einhorn L, Nichols CR, et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 2001; 19:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adra N, Abonour R, Althouse SK, et al. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. J Clin Oncol 2017; 35:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 1990; 322:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladanyi M, Samaniego F, Reuter VE, et al. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst 1990; 82:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orazi A, Neiman RS, Ulbright TM, et al. Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer 1993; 71:3873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor J, Donoghue MT, Ho C, et al. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest 2020; 130:6668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998; 159:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrlich Y, Beck SD, Ulbright TM, et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol 2010; 21:1846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguiar Bujanda D, Pérez Cabrera D, Croissier Sánchez L. Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: A Surveillance, Epidemiology, and End Results-based Study. Am J Clin Oncol 2022; 45:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funt SA, Patil S, Feldman DR, et al. Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. J Clin Oncol 2019; 37:2329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagrodia A, Lee BH, Lee W, et al. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. J Clin Oncol 2016; 34:4000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacon JVW, Giannatempo P, Cataldo G, et al. TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors. Oncologist 2022; 27:e912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmerman DM, Eleveld TF, Sriram S, et al. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors. J Clin Oncol 2022; 40:3077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAleer JJ, Nicholls J, Horwich A. Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours? Eur J Cancer 1992; 28A:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gatcombe HG, Assikis V, Kooby D, Johnstone PA. Primary retroperitoneal teratomas: a review of the literature. J Surg Oncol 2004; 86:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon SS, Tanabe KK, Warshaw AL. Adult primary retroperitoneal teratoma. Surgery 2005; 137:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JC, Shin JS, Huang YT, et al. Primary retroperitoneal teratoma in an adult. J Chin Med Assoc 2003; 66:497.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2998 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Wick MR, Perlman EJ, Orazi A, Muller-Hermelink HK. Germ cell tumours of the mediastinum. In: Tumours of the Lung, Pleura, Thymus and Heart, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16735707" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17471115" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8933567" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Intracranial germ cell tumors: a comprehensive review of proposed embryologic derivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749107" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetics and biology of adult human male germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9041167" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Primary mediastinal germ cell tumor with intratubular germ cell neoplasia of the testis--further support for germ cell origin of these tumors: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7910232" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Origin of adult male mediastinal germ-cell tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27032104" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Male Extragonadal Germ Cell Tumors of the Adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1327076" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15319245" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11717334" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16564924" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Extragonadal germ cell tumors are often associated with Klinefelter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16470792" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Klinefelter syndrome and mediastinal germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30291793" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Klinefelter syndrome in males with germ cell tumors: A report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33005196" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Klinefelter syndrome and germ cell tumors: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8648846" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Burned-out primary testicular cancer: sonographic and pathological characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16819328" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3007784" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Primary or secondary extragonadal germ cell tumors?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1375284" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9038622" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7505876" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation of six tumor markers in patients with carcinoma of unknown primary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16791594" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7799031" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11919246" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11919246" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6632945" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Benign teratomas of the mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1267292" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Teratoid tumors of the mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9258780" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mediastinal teratoma presenting as massive hemoptysis in an adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/103398" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Primary mediastinal seminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9308448" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mediastinal mature teratoma: imaging features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7689921" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Germ cell tumors of the mediastinum. A 30-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12518361" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9128238" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Videothoracoscopic removal of a mediastinal teratoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27621392" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31977510" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12673712" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9552027" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9066750" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Primary immature mediastinal teratoma in adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645417" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Chemotherapy for teratoma with malignant transformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264352" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283942" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9053482" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/55502" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2778480" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3598610" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8636757" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093705" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Residual mass following chemotherapy of seminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9291801" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533096" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18207171" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1313190" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Extragonadal germ cell tumors and unrecognized germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6204019" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The treatment of extragonadal seminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620634" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264353" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2981374" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Malignant germ cell tumors of the mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469363" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25456363" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25456363" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36223226" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Surgical treatment confers prognostic significance in pediatric malignant mediastinal germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157018" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19889611" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699894" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051766" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9261524" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1654195" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8021729" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11250992" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194867" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27870561" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158625" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Hematologic neoplasia associated with primary mediastinal germ-cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2153216" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8389653" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32897884" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400455" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231305" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36394133" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: A Surveillance, Epidemiology, and End Results-based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31233353" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27646943" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36166584" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35442716" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1381929" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15112254" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Primary retroperitoneal teratomas: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15933637" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Adult primary retroperitoneal teratoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14604315" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Primary retroperitoneal teratoma in an adult.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
